Heidelberg Pharma AG / Fundamentals
Income statement
- Net revenue
€5.70M - Cost of goods sold
€2.24M - Gross profit
€3.46M - SG&A expenses
€6.89M - R&D expenses
€23.61M - EBITDA
-€20.68M - D&A
€864.97K - EBIT
-€25.58M - Interest expenses
€41.23K - EBT
-€21.59M - Tax expenses
-€48.93K - Net income
-€21.54M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€1.29M - Changes in working capital
-€2.32M - Operating cash flow
-€24.37M - Capex
€406.00K - Other investing cash flow
€54.68K - Net investing cash flow
-€365.68K - Total cash dividends paid
€0.00 - Issuance of common stock
€22.76M - Debt repayment
-€24.52K - Other financing cash flow
€11.43M - Net financing cash flow
€34.16M - Foreign exchange effects
€17.83K - Net change in cash
€16.50M - Cash at end of period
€33.25M - Free cash flow
-€23.96M
Balance sheet
- Cash and cash equivalents
€33.25M - Cash and short-term investments
€33.25M - Total receivables
€2.59M - Inventory
€12.80M - Other current assets
€568.30K - Total current assets
€49.21M - Property, plant & equipment
€3.20M - Goodwill
€6.11M - Intangible assets
€2.73M - Long-term investments
€1.20M - Other non-current assets
€0.00 - Total non-current assets
€13.24M - Total assets
€62.45M - Accounts payable
€5.06M - Short-term debt
€97.20K - Other current liabilities
€1.21M - Total current liabilities
€6.36M - Long-term debt
€37.58M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€37.58M - Total liabilities
€43.94M - Common stock
€46.60M - Retained earnings
-€343.71M - Other equity
€0.00 - Total equity
€18.52M - Total liabilities and shareholders' equity
€62.45M
Company information
- Market capitalization
€228.35M - Employees
105 - Enterprise Value
€195.70M
Company ratios
- Gross margin
-
60.7% Better than peer group: 50.0% - EBITDA margin
-
-362.8% Much worse than peer group: -53.6% - EBIT margin
-
-448.7% Much worse than peer group: -80.6% - EBT margin
-
-378.7% Much worse than peer group: -82.6% - Net margin
-
-377.9% Much worse than peer group: -83.8% - ROE
-
-116.3% Much worse than peer group: 20.4% - ROA
-
-34.5% Much worse than peer group: -8.8% - Asset turnover
-
9.1% Much worse than peer group: 102.5% - FCF margin
-
-434.6% Much worse than peer group: -78.6% - FCF yield
-10.8% - Efficiency ratio
462.8% - Net sales per employee
-
€54.29K - Net income per employee
-
-€205.15K